Product image of Minatuss (Butamirate Citrate) supplied by GNH India

Minatuss

Active Ingredient:
Butamirate Citrate
Origin:
EU

Minatuss (Butamirate Citrate)

Butamirate citrate, the active ingredient in Minatuss, is an antitussive presented as an oral dosage form for oral use. It suppresses dry, non‑productive coughs in adults and adolescents and acts centrally to reduce the cough reflex without affecting mucus clearance.

GNH India supplies Minatuss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Manufacturer / TM Owner

Galenica Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Butamirate citrate is an antitussive that reduces the frequency of dry, non‑productive coughs.

  • Dry cough: provides symptomatic relief by decreasing cough frequency.
  • Non‑productive cough: alleviates throat irritation without affecting mucus clearance.
  • Cough associated with upper respiratory tract infections: helps control coughing episodes while the underlying infection resolves.

How It Works

  • Butamirate citrate acts centrally on the medullary cough centre in the brainstem. By modulating neuronal activity, it raises the threshold for cough initiation, thereby diminishing the cough reflex. The exact receptor interaction is not fully defined, but the effect is achieved without significant impact on respiratory secretions, allowing suppression of dry coughs while preserving normal airway clearance.

Side Effects

Butamirate citrate may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects

  • Nausea: mild stomach upset reported by some patients.
  • Dizziness: transient light‑headedness, especially after the first dose.
  • Drowsiness: occasional sleepiness, advise caution when driving.
  • Headache: mild to moderate headache in a minority of users.
  • Dry mouth: reduced salivation leading to throat discomfort.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, or angioedema requiring medical attention.
  • Severe dizziness or vertigo: may indicate central nervous system involvement.
  • Hallucinations or confusion: rare neuropsychiatric events.
  • Respiratory depression: extremely rare but serious, especially if combined with other depressants.

Precautions & Warnings

When prescribing or dispensing butamirate citrate, consider the following precautions.

  • Assess hypersensitivity: avoid use in patients with known allergy to butamirate citrate.
  • Hepatic impairment: use with caution and monitor liver function.
  • Concomitant CNS depressants: avoid or adjust dose if combined with other sedatives.
  • Excessive sedation: monitor patients for profound drowsiness or impaired coordination.
  • Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Butamirate citrate can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid)

  • Other centrally acting cough suppressants: may lead to excessive suppression of the cough reflex.
  • Monoamine oxidase inhibitors (MAOIs): risk of heightened central nervous system effects.

Moderate Interactions (Monitor Closely)

  • Alcohol: can increase drowsiness and dizziness.
  • Sedating antihistamines: may enhance sedation.
  • Opioid analgesics: additive central depressant effects.
  • Benzodiazepines: potential for increased sedation and respiratory depression.

Frequently Asked Questions

Minatuss contains butamirate citrate and is indicated for the symptomatic relief of dry, non‑productive coughs. It helps reduce the frequency and intensity of coughing episodes without affecting mucus production, making it suitable for adults and adolescents experiencing irritating coughs.

Butamirate citrate acts on the medullary cough centre in the brainstem, raising the threshold required to trigger a cough. By modulating neuronal activity centrally, it suppresses the cough reflex while preserving normal airway clearance, which is why it is effective for dry coughs.

The specific dose of Minatuss is determined by the prescribing healthcare professional based on the patient’s age, weight, and clinical condition. Patients should follow the prescriber’s instructions and the product label; no universal dosing regimen is provided here.

Safety data for butamirate citrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Minatuss product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Butamirate citrate differs from dextromethorphan, another common antitussive, by acting primarily on the medullary cough centre rather than NMDA receptors. Clinical experience suggests comparable efficacy for dry cough, but individual response and side‑effect profiles may vary, so choice depends on patient tolerance and physician preference.

Minatuss should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Minatuss is taken orally, usually with a glass of water. The tablet (or oral formulation) should be swallowed whole unless otherwise directed by a healthcare professional. It can be taken with or without food, but patients should follow the prescriber’s specific instructions.

Serious, though rare, risks include allergic reactions such as rash, angioedema, or severe dizziness, and in extremely uncommon cases, hallucinations or respiratory depression. Patients should seek immediate medical attention if they experience any signs of an allergic response or unexpected neurological symptoms.

Minatuss should be avoided in individuals with known hypersensitivity to butamirate citrate or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, and it should not be combined with other central cough suppressants or MAO inhibitors without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.